PDF(Pubmed)
Abstract：
OBJECTIVE: In hepatocellular carcinoma (HCC) treatment, radiotherapy (RT) stands as a pivotal approach, yet the emergence of radioresistance poses a formidable challenge. This study aimed to explore the potential synergy between quetiapine and RT for HCC treatment.
METHODS: A Hep3B xenograft mouse model was used, the investigation tracked tumor progression, safety parameters, and molecular mechanisms.
RESULTS: The findings revealed a synergistic anti-HCC effect when quetiapine was coupled with RT that prolonged tumor growth time and a significantly higher growth inhibition rate compared to the control group. Safety assessments indicated minimal pathological changes, suggesting potential of quetiapine in mitigating RT-induced alterations in liver and kidney functions. Mechanistically, the combination suppressed metastasis and angiogenesis-related proteins, while triggering the activation of apoptosis-related proteins via targeting Epidermal growth factor receptor (EGFR)-mediated signaling.
CONCLUSIONS: The potential of the quetiapine and RT combination is emphasized, offering enhanced anti-HCC efficacy, a safety profile, and positioning quetiapine as a radiosensitizer for HCC treatment.
METHODS: A Hep3B xenograft mouse model was used, the investigation tracked tumor progression, safety parameters, and molecular mechanisms.
RESULTS: The findings revealed a synergistic anti-HCC effect when quetiapine was coupled with RT that prolonged tumor growth time and a significantly higher growth inhibition rate compared to the control group. Safety assessments indicated minimal pathological changes, suggesting potential of quetiapine in mitigating RT-induced alterations in liver and kidney functions. Mechanistically, the combination suppressed metastasis and angiogenesis-related proteins, while triggering the activation of apoptosis-related proteins via targeting Epidermal growth factor receptor (EGFR)-mediated signaling.
CONCLUSIONS: The potential of the quetiapine and RT combination is emphasized, offering enhanced anti-HCC efficacy, a safety profile, and positioning quetiapine as a radiosensitizer for HCC treatment.
摘要：
目的：在肝细胞癌（HCC）治疗中，放射治疗(RT)是一种关键的方法，然而，抗辐射性的出现带来了巨大的挑战。本研究旨在探讨喹硫平与RT治疗HCC的潜在协同作用。
方法：使用Hep3B异种移植小鼠模型，调查追踪肿瘤进展,安全参数,和分子机制。
结果：研究结果表明，喹硫平与RT联用时具有协同的抗HCC作用，与对照组相比，延长了肿瘤生长时间和显着更高的生长抑制率。安全性评估表明病理变化很小，提示喹硫平在减轻RT诱导的肝肾功能改变方面的潜力。机械上,该组合抑制了转移和血管生成相关蛋白，同时通过靶向表皮生长因子受体（EGFR）介导的信号传导触发凋亡相关蛋白的激活。
结论：强调喹硫平和RT联合用药的潜力，提供增强的抗肝癌疗效，安全档案，并将喹硫平定位为肝癌治疗的放射增敏剂。
方法：使用Hep3B异种移植小鼠模型，调查追踪肿瘤进展,安全参数,和分子机制。
结果：研究结果表明，喹硫平与RT联用时具有协同的抗HCC作用，与对照组相比，延长了肿瘤生长时间和显着更高的生长抑制率。安全性评估表明病理变化很小，提示喹硫平在减轻RT诱导的肝肾功能改变方面的潜力。机械上,该组合抑制了转移和血管生成相关蛋白，同时通过靶向表皮生长因子受体（EGFR）介导的信号传导触发凋亡相关蛋白的激活。
结论：强调喹硫平和RT联合用药的潜力，提供增强的抗肝癌疗效，安全档案，并将喹硫平定位为肝癌治疗的放射增敏剂。
